2023
Crisis of the Clinical Trials Staff Attrition After the COVID-19 Pandemic
Sun G, Dizon D, Szczepanek C, Petrylak D, Sparks D, Tangen C, Lara P, Thompson I, Blanke C. Crisis of the Clinical Trials Staff Attrition After the COVID-19 Pandemic. JCO Oncology Practice 2023, 19: 533-535. PMID: 37285550, PMCID: PMC10424897, DOI: 10.1200/op.23.00152.Peer-Reviewed Original Research
2018
Antigen-Specific CD8 Lytic Phenotype Induced by Sipuleucel-T in Hormone-Sensitive or Castration-Resistant Prostate Cancer and Association with Overall Survival
Antonarakis ES, Small EJ, Petrylak D, Quinn DI, Kibel AS, Chang NN, Dearstyne E, Harmon M, Campogan D, Haynes H, Vu T, Sheikh NA, Drake CG. Antigen-Specific CD8 Lytic Phenotype Induced by Sipuleucel-T in Hormone-Sensitive or Castration-Resistant Prostate Cancer and Association with Overall Survival. Clinical Cancer Research 2018, 24: 4662-4671. PMID: 29858218, PMCID: PMC6481607, DOI: 10.1158/1078-0432.ccr-18-0638.Peer-Reviewed Original ResearchMeSH KeywordsAcid PhosphataseCD8-Positive T-LymphocytesCell Line, TumorCell ProliferationClinical Trials as TopicGene Expression Regulation, NeoplasticGranulocyte-Macrophage Colony-Stimulating FactorHumansLysosomal-Associated Membrane Protein 1MaleNeoplasm MetastasisNeoplasms, Hormone-DependentProstatic Neoplasms, Castration-ResistantRecombinant Fusion ProteinsTissue ExtractsT-Lymphocytes, CytotoxicConceptsSipuleucel-T treatmentMetastatic castration-resistant prostate cancerProstatic acid phosphataseOverall survivalCTL activityWeek 26Immune responseWeek 6Peripheral cellular immune responsesCytotoxic T lymphocyte activityCastration-resistant prostate cancerEfficacy of sipuleucelImproved overall survivalMedian overall survivalT lymphocyte activityT cell responsesCellular immune responsesT cell proliferationClin Cancer ResHealthy volunteer samplesCD107a expressionLonger OSLymphocyte activityCytolytic responsesTertile analysis
2000
Colitis and docetaxel-based chemotherapy
Kreis W, Petrylak D, Savarese D, Budman D. Colitis and docetaxel-based chemotherapy. The Lancet 2000, 355: 2164. PMID: 10902651, DOI: 10.1016/s0140-6736(05)72789-6.Peer-Reviewed Original Research
1999
Chemotherapy for advanced hormone refractory prostate cancer
Petrylak D. Chemotherapy for advanced hormone refractory prostate cancer. Urology 1999, 54: 30-35. PMID: 10606282, DOI: 10.1016/s0090-4295(99)00452-5.Peer-Reviewed Original ResearchConceptsHormone-refractory prostate cancerRefractory prostate cancerProstate-specific antigenProstate cancerBone painAdvanced hormone-refractory prostate cancerHormone-resistant prostate cancerSerum prostate-specific antigenCombination of estramustinePhase III studySoft tissue metastasesTaxane-based therapyCombination of mitoxantroneMetastatic prostate cancerDrug Administration approvalCorticosteroid therapyHormone therapyIII studyTissue metastasesRandomized trialsTreatment optionsHistorical controlsAdministration approvalClinical practiceUS Food
1993
Cytotoxic chemotherapy for advanced hormone‐resistant prostate cancer
Yagoda A, Petrylak D. Cytotoxic chemotherapy for advanced hormone‐resistant prostate cancer. Cancer 1993, 71: 1098-1109. PMID: 7679039, DOI: 10.1002/1097-0142(19930201)71:3+<1098::aid-cncr2820711432>3.0.co;2-g.Peer-Reviewed Original ResearchMeSH KeywordsAntibodies, MonoclonalAntineoplastic AgentsBone NeoplasmsCisplatinClinical Trials as TopicCoumarinsDoxorubicinDrug Administration ScheduleDrug ResistanceFluorouracilHumansIntercalating AgentsMaleMethotrexateNeoplasm StagingPolyaminesProstate-Specific AntigenProstatic NeoplasmsRemission InductionSomatostatinConceptsDrug trialsAdvanced hormone-resistant prostate cancerHormone-resistant prostate cancerObjective response rateCombination of vinblastineMost cytotoxic agentsReliable disease markersNew drug trialsProstate cancer cellsCurrent reviewNew therapeutic agentsPartial remissionVisceral metastasesAdvanced adenocarcinomaCytotoxic chemotherapyObjective responseContinuous infusionNonresponsive tumorsMarginal efficacyHormonal manipulationProstate cancerNew agentsResponse rateCytotoxic drugsTherapeutic agents